anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a copper-nitroimidazole complex which is formed by self-assembling copper ions and 2-nitroimidazole coordination. The complex only comprises copper ions and 2-nitroimidazole, and the simple two-component combination can realize the chemical kinetics treatment of GSH metabolism enhancement and induce iron death. The copper-nitroimidazole complex has GSH response and hypoxia response as nano-drugs, and can selectively act in tumor cells. The nano medicine releases copper ions and 2-nitroimidazole in tumor cells, the 2-nitroimidazole consumes NADPH under the condition of hypoxia so as to prevent GSH synthesis, and the copper ions are the sameGSH is consumed. Consumption of GSH enhances Cu  2+  /Cu  +  Active oxygen produced by the mediated Fenton reaction. The 2-nitroimidazole and the copper ions are self-assembled to form the nano-drug, so that the loading capacity of the 2-nitroimidazole is greatly improved.
The invention provides a preparation method of a human stem cell for continuously secreting active chondroitinase ABC. The preparation method comprises constructing an N-terminal signal peptide-free chondroitinase ABC gene, adding a gene segment for transcription and translation improvement to the end 3' of the gene, constructing the recombinant gene to a virus vector, and transfecting a human stem cell to obtain the human stem cell for continuously secreting active chondroitinase ABC. The human stem cell can effectively secrete chondroitinase ABC for a long time. The chondroitinase ABC has enzyme activity at a temperature of -20 DEG C for a long time. The invention provides a clinical use of the human stem cell continuously secreting active chondroitinase ABC. Through seed cells and a microenvironment going against nerve regeneration, the human stem cell can produce dual effects of treating chronic neurodegenerative diseases.
OBJECTIVES: I. Determine the safety and tolerability of gemcitabine plus oxaliplatin in patients with refractory metastatic or locally advanced pancreatic cancer (phase I portion of the study closed as of 7/5/00). II. Determine the objective tumor response rate to this combination regimen in this patient population.

OUTLINE: This is a dose escalation and efficacy study. Patients receive gemcitabine IV over 30 minutes on days 1 and 8 immediately followed by oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks. Patients achieving stable disease, partial response, or regressive disease continue with therapy. Patients achieving complete response for two consecutive evaluations receive an additional 2 courses of therapy. Phase I (closed as of 7/5/00): Cohorts of 3-6 patients receive escalating doses of gemcitabine and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Phase II: Patients receive the MTD of gemcitabine and oxaliplatin as in phase I. Patients are followed every 3 months for 1 year, and then every 6 months for 4 years.

PROJECTED ACCRUAL: A total of 32-52 patients (12 patients to phase I (phase I closed as of 7/5/00) and 20-40 to phase II) will be accrued for this study within approximately 11-28 months.
The novel term Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is proposed to replace non-alcoholic fatty liver disease (NAFLD) to highlight the close association with the metabolic syndrome. MASLD encompasses patients with liver steatosis and at least one of five cardiometabolic risk factors which implies that these patients are at increased risk of cardiovascular disease (CVD). Indeed, the prevalence of CVD in MASLD patients is increased and CVD is recognized as the most common cause of death in MASLD patients. We here present an update on the pathophysiology of CVD in MASLD, discuss the risk factors, and suggest screening for CVD in patients with MASLD. Currently, there is no FDA-approved pharmacological treatment for MASLD, and no specific treatment recommended for CVD in patients with MASLD. Thus, the treatment strategy is based on weight loss and a reduction and treatment of CVD risk factors. We recommend screening of MASLD patients for CVD using the SCORE2 system with guidance to specific treatment algorithms. In all patients with CVD risk factors, lifestyle intervention to induce weight loss through diet and exercise is recommended. Especially a Mediterranean diet may improve hyperlipidemia and if further treatment is needed, statins should be used as first-line treatment. Further, anti-hypertensive drugs should be used to treat hypertension. With the epidemic of obesity and type 2 diabetes mellitus (T2DM) the risk of MASLD and CVD is expected to increase, and preventive measures, screening, and effective treatments are highly needed to reduce morbidity and mortality in MASLD patients.
<P>PROBLEM TO BE SOLVED: To provide a superior beauty and health food in the form of a capsule/drink which shows acceleration of absorbing/forming elastin and collagen, and prevents the ageing of cells from inside the body by antioxidation effect and improvement of component stabilization to be brimful of youthful vitality and keep fit.  <P>SOLUTION: The beauty and health food is obtained by incorporating at least one component of a Rhodiola rosea L. root extract, an extract of sake lees, and an olive leaf extract into a shark fin extract, yolk lecithin, and fermentation aged collagen (LCP). Particularly, the beauty and health food in the form of a capsule is obtained by incorporating at least one component of vitamin E, vitamin C, vitamin B1, vitamin B2, and vitamin B6 into the shark fin extract, the yolk lecithin, and the fermentation aged collagen (LCP) or the beauty and health food in the form of a drink is obtained by incorporating at least one component of royal jelly, Pycnogenol (TM), hyaluronic acid, an olive leaf extract, Coix lachryma-jobi var. ma-yuen. , sake lees extract, and Rhodiola rosea L. root extract into the above fermentation aged collagen (LCP).  <P>COPYRIGHT: (C)2008,JPO&INPIT
Patients receive 17-AAG IV over 1-2 hours twice weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
PURPOSE OF REVIEW: The goal of this review was to examine the role and practical applications of integrative oncology strategies in supporting immune checkpoint inhibitor (ICI) treatment of adult solid tumours.
RECENT FINDINGS: Beyond tumour-intrinsic factors, several patient-associated factors affect ICI response, including germline genetics, systemic inflammation, the gut microbiota, and diet. Current promising supportive interventions include a Mediterranean-style diet with over 20 g of fibre, regular exercise, use of live biotherapeutics, minimisation of PPI and antibiotic use, and ensuring vitamin D repletion, with many other integrative oncology approaches under study. Caution around medical cannabis use in patients on ICIs is advised due to previously documented adverse impact on overall survival, while VAE (Viscum album extract) therapy studies have not highlighted any safety concerns so far. With expanding ICI use, it is important to investigate and apply low-cost integrative oncology strategies to support better treatment outcomes and minimise adverse events. Further research may lead to pre-treatment assessment of both tumour and patient-associated biomarkers and personalised multimodal prehabilitation care plans, as well as on-treatment support with targeted nutrition, physical activity, and supplementation regimes, including both systemic inflammation and gut microbiome modulating strategies. Given the emerging understanding of chronic stress impact on ICI treatment outcomes, mind-body approaches require further investigation.
This is a phase I single center open label trial study that will enroll twenty-six (26) patients requiring semi-elective lower extremity major amputation within a 30 day period for non-infectious complications related to critical limb ischemia (CLI). After enrollment patients will be scheduled for amputation 7 days after MSC administration. The investigational treatment uses allogeneic bone marrow derived mesenchymal stem cells at the point of care. Allogeneic MSCs will be injected in the gastrocnemius muscle and anterior tibialis muscle of twenty-six (26) patients undergoing major amputation. Through a review of treatment related adverse events over 6 months we will test the hypothesis that allogeneic MSCs do not result in significant cardiovascular, respiratory, or infectious treatment related adverse events. Through an exploratory investigation we will assess the efficacy of MSCs in promoting freedom from gangrene, revision of amputation, and death after major amputation.
PURPOSE: To obtain a liquid 1-n-menthol composition capable of inexpensively feeding, improving refreshing feeling of menthol (especially bitterness) and utilizing to uses for which conventional menthol is used. CONSTITUTION: The characteristic of this liquid 1-n-menthol composition comprises containing 30-80wt.% of (-)-n-isopulegol. The characteristic of this method for preparing the liquid 1-n menthol composition comprises mixing a liquid menthol having >=42 deg.C melting point and obtained in 1-n-menthol producing process with 30-80wt.% of (-)-n-isopulegol. The characteristic of the liquid 1-n-menthol composition and its preparation comprises exchanging a part of (-)-n-isopulegol with 3-1-n-menthoxypropane-1,2-diol. Excellent effect can be obtained also from the viewpoint of workability and hygienical face. Perfume of menthol and irritation feeling to skin are relieved and mildness can be increased.
Primary graft dysfunction (PGD) is a life-threatening clinical condition with a high mortality rate, presenting as left, right, or biventricular dysfunction within the initial 24 h following heart transplantation, in the absence of a discernible secondary cause. Given its intricate nature, definitive definition and diagnosis of PGD continues to pose a challenge. The pathophysiology of PGD encompasses numerous underlying mechanisms, some of which remain to be elucidated, including factors like myocardial damage, the release of proinflammatory mediators, and the occurrence of ischemia-reperfusion injury. The dynamic characteristics of both donors and recipients, coupled with the inclination towards marginal lists containing more risk factors, together contribute to the increased incidence of PGD. The augmentation of therapeutic strategies involving mechanical circulatory support accelerates myocardial recovery, thereby significantly contributing to survival. Nonetheless, a universally accepted treatment algorithm for the swift management of this clinical condition, which necessitates immediate intervention upon diagnosis, remains absent. This paper aims to review the existing literature and shed light on how diagnosis, pathophysiology, risk factors, treatment, and perioperative management affect the outcome of PGD.
The present invention provides a combination treatment method for reducing the volume of, or inhibiting the growth of, a sarcoma, carcinoma, or other solid tumor cancer, in a subject by administering to the subject in need of such treatment, an effective dose of irradiation and an effective amount of tumor-targeted facultative aerobic or facultative anaerobic bacteria. In one embodiment, the tumor-targeted bacteria are super-infective. In another embodiment, the bacteria have been genetically engineered to express a gene product(s) of interest and serve as a bacterial vector which gene product aids in reducing the volume of, or inhibiting the growth of, the solid tumor cancer. The gene product of interest is selected from the group consisting of proteinaceous and nucleic acid molecules. In a preferred embodiment, the bacteria or bacterial vector is attenuated. In another preferred embodiment, the bacterial vector is a tumor-targeted, attenuated vector expressing a gene product of interest which aids in reducing the volume, or inhibiting the growth of the tumor. The present invention is based, in part, on the surprising discovery that a combination method of administering one or more doses of irradiation and tumor-targeted facultative aerobic or facultative anaerobic bacteria results in greater tumor volume reduction and tumor growth inhibition than would be expected. The bacteria can also be genetically engineered to be more responsive to DNA damaging agents, such as ionizing radiation. The combination methods of the present invention give an enhanced effect, i.e., more than the additive effect expected following administration of tumor-targeted bacteria and irradiation together.
BACKGROUND: Non-tuberculous mycobacteria (NTM) are rare causes of bone and joint infection (BJI) and there is limited evidence on which to base management decisions. This study describes 1 year of experience from a multi-disciplinary BJI team which collects data on all cases reviewed at a tertiary referral centre in Queensland, Australia.
METHODS: The database was interrogated for all cases in which NTM were recovered from operative samples. Individual chart review was performed to collect the details of each case.
RESULTS: A total of seven cases were managed between 1st February 2021 and 28th February 2022, comprising one patient with chronic osteomyelitis, three with fracture-related infections, two with prosthetic joint infections, and one with infection of a synthetic ligament graft. In contrast to pulmonary NTM infections, most patients were clinically well and immunocompetent, and most infections were propagated by direct inoculation. Time to diagnosis was unknown in three patients, with 1, 2, 2, and 5 months for the remaining four. Rapid growing NTM were diagnosed on routine cultures and specific mycobacterial cultures were confirmatory. Management was characterized by multiple stage surgical procedures and prolonged antimicrobial regimens.
CONCLUSIONS: Antimicrobial complications were common; however, all patients were infection free at their latest follow up. Despite the inherent limitations, these results suggest that routinely ordering mycobacterial culture is of low yield. There is potential for shorter-term oral antimicrobial treatments. Prospective research is required to optimize treatment regimens and durations.
<P>PROBLEM TO BE SOLVED: To provide an anti-cancer phosphonate analogue, relating to compounds having anti-cancer activity.  <P>SOLUTION: By a method and a composition which make cells accumulate or hold a biologically active medicine in them, cell targeting can be done. The invention provides a new analogue of an anti-cancer compound. Such new analogues of anti-cancer compounds have all of the usefulness of the anti-cancer compounds, and optionally provide accumulation in cells described below. Furthermore, the invention provides a compound and a method for therapy of cancer or therapeutic activity to cancer.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Fucoidan, a polysaccharide derived from brown seaweeds, especially Fucus Vesiculosus has been documented as an effective neuroprotectant. This study investigates the efficacy of fucoidan in mitigating the cognitive deficits in the rat model of vascular dementia induced through the 4-vessel occlusions (4VO) method. Male Wistar rats weighing about 250-300 g were randomly assigned into four groups, sham, lesion (4VO), 4VO + F5mg/kg, and 4VO + F50mg/kg. The rats were assessed for cognitive behaviour performance through novel object task, T-maze and Morris water maze, and finally, the hippocampus from the brain was harvested to quantify the profile of CA1 pyramidal neurons through CFV staining and the expression of inflammatory markers and angiogenic markers were quantified through western blot assessment on day7 and 30 of the study period. The rats were treated with fucoidan at a dose of 50 mg/kg. body weight showed improved spatial learning and memory compared to the lesion group and the cytoarchitecture of CA1 pyramidal cells was observed to be well preserved. The expression of IL1β, IL6, TNFα, NFk-B, CD68 and HIFα were found to be down-regulated, while on the contrary the VEGFR2 and angiopoietin-1 were up regulated in the 4VO + F50mg/kg group when compared with the lesion group. In conclusion, this study ascertains the role of fucoidan in support of the cognitive profile of rats subjected to vascular dementia and in preserving the CA1 pyramidal neurons of the hippocampus by regulating the inflammatory and angiogenic factors.
Lipid compositions and lipid compositions included in cosmetic products, personal care products, skin care products, nutraceuticals, bio fuels, bio-lubricants, oleo chemicals, nutritional products, other bio-products, and animal feed compositions. Concentrations of lipid components. A method of removing and recovering a lipid composition by mixing a lipid feedstock with a solvent, separating the mixture into a raffinate phase and an extract phase containing beneficial non-glyceride compounds, removing solvent from the extract phase and obtaining a concentrate phase, and recovering a lipid composition from the concentrate phase. A method of producing a fatty acid alkyl ester. A method of producing a distiller's product. A method of performing secondary extractions and recovering a lipid composition by performing a first extraction on a lipid feedstock, performing a second extraction on a lipid feedstock, and exploiting differences in solubility limits to create unique product fractions derived from naturally occurring lipids.
Folate: Allergic sensitizations have been reported following both oral and parenteral administration of folate. 

Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving  Finazol™ after meals may control occasional gastrointestinal disturbances. Finazol™ is best absorbed when taken at bedtime. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic and idiosyncratic reactions are possible at lower levels. Iron, even at the usual recommended levels, has been associated with gastrointestinal intolerance in some patients.
Growth factors are of great potential in regenerative medicine. However, their clinical applications are largely limited by short in vivo half-lives and a narrow therapeutic window. Thus, a robust controlled release system remains an unmet medical need for growth-factor-based therapies. A nanoscale controlled release system (degradable protein nanocapsule) is provided via in-situ polymerization on growth factor. The release rate can be finely tuned by engineering the surface polymer composition. Improved therapeutic outcomes are achieved with the growth factor nanocapsules, as illustrated in spinal cord fusion mediated by bone morphogenetic protein-2 (BMP-2) nanocapsules.
Manifestations of magnesium toxicity include a drop in blood pressure, difficulty breathing, and disappearance of the patellar reflex. As serum magnesium rises above 4 mEq per liter, the deep tendon reflexes decrease. As the serum magnesium level approaches 10 mEq per liter, the tendon reflexes disappear and respiratory paralysis may occur [see Warnings and Precautions (5.2)]. Other signs and symptoms of magnesium overdosage include flushing, sweating, hypotension, weakness, hypothermia, circulatory collapse, cardiac and central nervous system depression proceeding to respiratory paralysis, cardiac arrest, and prolongation of PR and QRS intervals. Patients with renal impairment and underlying neuromuscular diseases such as myasthenia gravis may experience magnesium intoxication at lower magnesium concentrations (Magnesium Sulfate in 5% Dextrose Injection is contraindicated in patients with myasthenia gravis). 

If patient is experiencing magnesium toxicity, immediately discontinue Magnesium Sulfate in 5% Dextrose Injection. Artificial respiration may be required. Administer an injectable calcium salt to counteract the potential hazards of magnesium toxicity [see Warnings and Precautions (5.2)]. 

Hypermagnesemia in the newborn (after administration of Magnesium Sulfate in 5% Dextrose Injection to the mother) may require resuscitation and assisted ventilation via endotracheal intubation or intermittent positive pressure ventilation as well as intravenous calcium.
Postpartum sleep disruption is a risk factor for postpartum depression (PPD) as well as a potential treatment target. In the first 6 months after delivery, when the risk of PPD is greatest, fragmented maternal sleep is most often related to necessary infant night feedings. Clinicians' conversations about planning for and navigating postpartum sleep should include questions about patient expectations, cultural traditions, and available support. For women at high risk of PPD, or with moderate to severe PPD or other symptoms of mental illness, protecting one 4-5 hour period of consolidated nighttime sleep may be necessary and effective. This can be achieved by having another adult step in for 1-2 infant night feedings or by employing other strategies. OBs can encourage high-risk patients to develop a postpartum plan for sleep protection by initiating this conversation during pregnancy.
<P>PROBLEM TO BE SOLVED: To provide a sports electronic training system with electronic gaming functions, and applications thereof.  <P>SOLUTION: The sports electronic training system with electronic gaming functions and applications thereof are disclosed. In one embodiment, the system includes at least one monitor and a portable electronic processing device to receive data from the at least one monitor and provide feedback to an individual based on the received data. The monitor can be a motion monitor to measure the performance of the individual such as the running speed, pace and distance for a runner. Other monitors may include a heart rate monitor, a temperature monitor and an altimeter. In one embodiment, an input is provided to an electronic game based on data obtained from at least one monitor that affects an avatar, a digitally created character 4505, an action within the game or a game score of the electronic game.  <P>COPYRIGHT: (C)2009,JPO&INPIT